Stephen A Abraham, MD | |
55 Fruit Street, Massachusetts General Hospital, Boston, MA 02114 | |
(617) 726-9292 | |
Not Available |
Full Name | Stephen A Abraham |
---|---|
Gender | Male |
Speciality | Cardiovascular Disease (cardiology) |
Experience | 40 Years |
Location | 55 Fruit Street, Boston, Massachusetts |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1487743316 | NPI | - | NPPES |
3093662 | Medicaid | MA |
Facility Name | Location | Facility Type |
---|---|---|
Massachusetts General Hospital | Boston, MA | Hospital |
North Shore Medical Center - | Salem, MA | Hospital |
Brigham And Women's Hospital | Boston, MA | Hospital |
Winchester Hospital | Winchester, MA | Hospital |
Melrosewakefield Healthcare | Melrose, MA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Massachusetts General Physicians Organization Inc | 2466365820 | 3085 |
North Suburban Cardiology Associates P.c. | 7517859879 | 6 |
News Archive
As the Institute for Health Technology Studies (InHealth) marks its five-year milestone, the research and educational nonprofit is taking stock of its contributions to objective evidence about the roles that medical technologies play in the economy, in the healthcare system, and in patients' lives.
The U.S. Food and Drug Administration today issued draft guidance that clarifies when changes or modifications to a previously cleared 510(k) device require a new premarket submission.
Every two minutes, a child will die from malaria in Africa. It is a preventable, treatable disease, that each year affects approximately 200 million people globally.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
› Verified 4 days ago
Entity Name | Massachusetts General Physicians Organization Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1801874573 PECOS PAC ID: 2466365820 Enrollment ID: O20031111000434 |
News Archive
As the Institute for Health Technology Studies (InHealth) marks its five-year milestone, the research and educational nonprofit is taking stock of its contributions to objective evidence about the roles that medical technologies play in the economy, in the healthcare system, and in patients' lives.
The U.S. Food and Drug Administration today issued draft guidance that clarifies when changes or modifications to a previously cleared 510(k) device require a new premarket submission.
Every two minutes, a child will die from malaria in Africa. It is a preventable, treatable disease, that each year affects approximately 200 million people globally.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
› Verified 4 days ago
Entity Name | Middlesex Cardiology Assoc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1508927922 PECOS PAC ID: 9436137387 Enrollment ID: O20040708000875 |
News Archive
As the Institute for Health Technology Studies (InHealth) marks its five-year milestone, the research and educational nonprofit is taking stock of its contributions to objective evidence about the roles that medical technologies play in the economy, in the healthcare system, and in patients' lives.
The U.S. Food and Drug Administration today issued draft guidance that clarifies when changes or modifications to a previously cleared 510(k) device require a new premarket submission.
Every two minutes, a child will die from malaria in Africa. It is a preventable, treatable disease, that each year affects approximately 200 million people globally.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
› Verified 4 days ago
Entity Name | North Suburban Cardiology Associates P.c. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1376515809 PECOS PAC ID: 7517859879 Enrollment ID: O20040823000780 |
News Archive
As the Institute for Health Technology Studies (InHealth) marks its five-year milestone, the research and educational nonprofit is taking stock of its contributions to objective evidence about the roles that medical technologies play in the economy, in the healthcare system, and in patients' lives.
The U.S. Food and Drug Administration today issued draft guidance that clarifies when changes or modifications to a previously cleared 510(k) device require a new premarket submission.
Every two minutes, a child will die from malaria in Africa. It is a preventable, treatable disease, that each year affects approximately 200 million people globally.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
› Verified 4 days ago
Entity Name | The General Hospital Corporation |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1023049236 PECOS PAC ID: 6507803806 Enrollment ID: O20080313000351 |
News Archive
As the Institute for Health Technology Studies (InHealth) marks its five-year milestone, the research and educational nonprofit is taking stock of its contributions to objective evidence about the roles that medical technologies play in the economy, in the healthcare system, and in patients' lives.
The U.S. Food and Drug Administration today issued draft guidance that clarifies when changes or modifications to a previously cleared 510(k) device require a new premarket submission.
Every two minutes, a child will die from malaria in Africa. It is a preventable, treatable disease, that each year affects approximately 200 million people globally.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Stephen A Abraham, MD 55 Fruit Street, Massachusetts General Hospital, Boston, MA 02114 Ph: (617) 726-9292 | Stephen A Abraham, MD 55 Fruit Street, Massachusetts General Hospital, Boston, MA 02114 Ph: (617) 726-9292 |
News Archive
As the Institute for Health Technology Studies (InHealth) marks its five-year milestone, the research and educational nonprofit is taking stock of its contributions to objective evidence about the roles that medical technologies play in the economy, in the healthcare system, and in patients' lives.
The U.S. Food and Drug Administration today issued draft guidance that clarifies when changes or modifications to a previously cleared 510(k) device require a new premarket submission.
Every two minutes, a child will die from malaria in Africa. It is a preventable, treatable disease, that each year affects approximately 200 million people globally.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
› Verified 4 days ago